Mario C. Deng

TL;DR: A comprehensive in silico cancer vs. benign analysis of the Mediator complex subunits (MEDs) for 20 tumor entities showed differentially expressed MEDs as compared to benign tissue, revealing that MEDs do exhibit cancer specific transcriptional expression profiles.

TL;DR: Data from early breakthrough studies, more recent observational cohort studies, and studies testing other therapies in advanced heart failure must be analyzed to characterize clinical profiles of patients who should be considered too well for cardiac transplantation at specific stages of their disease processes.

TL;DR: The various decision‐making branching points that were made in the AlloMap biomarker test development are discussed to inform future genomic biomarkers test development projects.

TL;DR: Differences in sensitization patterns in patients receiving axial flow, implantable VADs versus pulsatile, paracorporeal biventricular assist devices (BIVADs) as bridges to transplantation suggest that the mechanism of sensitization between VAD and BIVAD patients may differ, and further mechanistic studies into the impact of device types on patient sensitization are warranted.

TL;DR: The aberrant state of monocyte and T-cell activation resulting from these host-device interaction is accompanied by two parallel processes, and on the other hand the VAD recipient is more likely to develop allosensitization, posing a significant risk to successful transplant outcome.